Pfizer's long-awaited Lyme disease vaccine has encountered a setback in its final-stage clinical trial, missing its primary statistical endpoint despite showing signs of efficacy. The pharmaceutical giant announced it still intends to pursue regulatory approval for the experimental shot.
Lyme disease affects nearly half a million Americans annually, making it a significant public health concern. The development of an effective vaccine has been a priority for years, as the tick-borne illness can cause serious complications if left untreated.